CancerVax said positive Phase 3 results from Moderna and Merck's INTerpath-001 trial support the LNP-mRNA technology used in its own preclinical cancer vaccine platform. The Aug. 19, 2026, results showed that intismeran autogene, also known as mRNA-4157/V940, combined with KEYTRUDA met the primary endpoint of recurrence-free survival in patients with completely resected stage IIB-IV melanoma. CancerVax is developing non-personalized, off-the-shelf injections intended to make cancer cells resemble familiar viral infections and activate pre-existing antiviral immunity. The company contrasts this approach with personalized cancer vaccines, which require tumor sequencing and custom manufacturing for each patient and may be expensive and difficult to scale. CancerVax Chief Scientific Officer Dr. George Katibah said the results strengthen the scientific rationale for using mRNA to direct immune responses against cancer, while noting that CancerVax uses predetermined immune targets recognized by up to 99% of the human population. The company remains in preclinical development and cautioned that its forward-looking statements are subject to uncertainty and may differ materially from actual results.